2024
Real World Data on Efficacy and Safety of EPOCH in T-Cell Lymphoma
Straining R, Foss F, Schiffer M, Amin K, Agarwal S, Isufi I, Huntington S, Kothari S, Seropian S, Girardi M, Sethi T. Real World Data on Efficacy and Safety of EPOCH in T-Cell Lymphoma. Clinical Lymphoma Myeloma & Leukemia 2024 PMID: 39368885, DOI: 10.1016/j.clml.2024.09.005.Peer-Reviewed Original ResearchT-cell lymphomaHeterogeneous group of lymphoid malignanciesGroup of lymphoid malignanciesPeripheral T-cell lymphomaAggressive T-cell lymphomaCutaneous T-cell lymphomaT cellsResponse rateR/R settingComplete responseLymphoid malignanciesPoor outcomeAnaplastic large cell lymphomaFrontline treatment regimensLarge cell lymphomaCombination of prednisoneHeterogeneous groupCell lymphomaChemotherapy optionsCaucasian patientsFirst-linePositive patientsTreatment regimensGrade 3Lymphoma
2022
Peripheral Blood Involvement at Staging in Patients With Aggressive Peripheral T-Cell Lymphoma
Avery J, Chandhok N, Rainey C, Torres R, Huntington S, Isufi I, Seropian S, Xu ML, Foss F. Peripheral Blood Involvement at Staging in Patients With Aggressive Peripheral T-Cell Lymphoma. Clinical Lymphoma Myeloma & Leukemia 2022, 22: 680-689. PMID: 35568635, DOI: 10.1016/j.clml.2022.04.019.Peer-Reviewed Original ResearchConceptsPeripheral T-cell lymphomaT-cell lymphomaBone marrow involvementBlood involvementFlow cytometryMarrow involvementNodal subtypesAggressive peripheral T-cell lymphomaNodal T-cell lymphomasNegative flow cytometryPeripheral blood involvementPositive flow cytometryMalignant T cellsMalignant tumor cellsMedian PFSTime ofdiagnosisOverall survivalLymph nodesPoor outcomeDisease stagePeripheral bloodT cellsPrognostic measuresRare subgroupLymphoma
2020
Weekly Dosing Schedule of Brentuximab Vedotin in Mycosis Fungoides/Sezary Syndrome and Aggressive T Cell Lymphomas
Lee M, Schiffer M, Isufi I, Huntington S, Xu M, Seropian S, Gowda L, Kothari S, Girardi M, Foss F. Weekly Dosing Schedule of Brentuximab Vedotin in Mycosis Fungoides/Sezary Syndrome and Aggressive T Cell Lymphomas. Blood 2020, 136: 21-22. DOI: 10.1182/blood-2020-139790.Peer-Reviewed Original ResearchT-cell lymphomaAggressive T-cell lymphomaWeekly dosing scheduleMycosis fungoides/Sezary syndromeMF/SSWeekly dosingCell lymphomaDosing schedulesBrentuximab vedotinSezary syndromeGamma-delta T-cell lymphomaWeekly scheduleNK-T cell lymphomaAngioimmunoblastic T-cell lymphomaPeripheral T-cell lymphomaAnaplastic large cell lymphomaCancer response rateIncidence of neuropathyWeekly x 3Prospective clinical trialsStem cell transplantAdult T-cell leukemiaLarge cell lymphomaT-cell leukemiaDose weekly
2017
Transplantation in the Treatment of Primary Cutaneous Aggressive Epidermotropic Cytotoxic CD8-Positive T-Cell Lymphoma
Cyrenne BM, Gibson JF, Subtil A, Girardi M, Isufi I, Seropian S, Foss F. Transplantation in the Treatment of Primary Cutaneous Aggressive Epidermotropic Cytotoxic CD8-Positive T-Cell Lymphoma. Clinical Lymphoma Myeloma & Leukemia 2017, 18: e85-e93. PMID: 29223388, DOI: 10.1016/j.clml.2017.11.004.Peer-Reviewed Original ResearchConceptsHematopoietic stem cell transplantationT-cell lymphomaAllogeneic hematopoietic stem cell transplantationNovel agentsPeripheral T-cell lymphomaPositive T-cell lymphomaDiagnosis of CD8Retrospective case seriesStandardized treatment strategyStem cell transplantationPotential curative therapyCourse of treatmentPromising treatment modalityHistone deacetylase inhibitorsSustained remissionCombination chemotherapyCurative therapyCase seriesPoor outcomeRare subtypeTreatment courseAvailable therapiesCell transplantationTreatment modalitiesTreatment strategies
2013
Cytotoxic and Gamma-Delta Subtypes Of Peripheral T-Cell Lymphoma: A Single Center Experience
Fraser J, Subtil A, Alpdogan O, Seropian S, Cooper D, Xu M, Foss F. Cytotoxic and Gamma-Delta Subtypes Of Peripheral T-Cell Lymphoma: A Single Center Experience. Blood 2013, 122: 5092. DOI: 10.1182/blood.v122.21.5092.5092.Peer-Reviewed Original ResearchGamma-delta T-cell lymphomaT-cell lymphomaCutaneous gamma-delta T-cell lymphomaHepatosplenic T-cell lymphomaPeripheral T-cell lymphomaStem cell transplantationInitial therapyCell transplantationLymphoid neoplasmsPrimary cutaneous gamma-delta T-cell lymphomaGamma delta T-cell receptorInitiation of chemotherapySingle-center experienceAggressive clinical courseOff-label useT-cell NHLT cell receptorAdvisory CommitteeAcute GVHDAlloBMT patientsMedian followSalvage therapyAdditional therapyB symptomsFirst remissionA Pilot Study Of Sorafenib In Refractory Or Relapsed T-Cell Lymphoma Patients
Fraser J, Lansigan F, Seropian S, Barbarotta L, Foss F. A Pilot Study Of Sorafenib In Refractory Or Relapsed T-Cell Lymphoma Patients. Blood 2013, 122: 4356. DOI: 10.1182/blood.v122.21.4356.4356.Peer-Reviewed Original ResearchPeripheral T-cell lymphomaCutaneous T-cell lymphomaT-cell lymphomaRefractory T-cell lymphomaStarting doseStage IIBSkin toxicityPilot studyClinical activityRelapsed T-cell lymphomaAllogeneic stem cell transplantAngioimmunoblastic T-cell lymphomaT-cell lymphoma patientsPlatelet-derived growth factor receptor alphaProgression-free survivalStem cell transplantDuration of responseGrowth factor receptor alphaOff-label useT-cell NHLNumber of therapiesMulti-kinase inhibitorAdvisory CommitteeClinical CRStable disease
2010
A Phase 1 Trial of Vorinostat and Pegylated Liposomal Doxorubicin In Relapsed or Refractory Lymphoma.
Lansigan F, Seropian S, Cooper D, Potter V, Sowers N, Foss F. A Phase 1 Trial of Vorinostat and Pegylated Liposomal Doxorubicin In Relapsed or Refractory Lymphoma. Blood 2010, 116: 2816. DOI: 10.1182/blood.v116.21.2816.2816.Peer-Reviewed Original ResearchDose level 3Stem cell transplantStable diseaseHL patientsHodgkin's lymphomaPartial responseRefractory lymphomaCell transplantCardiac toxicityDisease progressionLiposomal doxorubicinLymphoplasmacytic lymphomaGrade 3Prior treatmentAST/ALT elevationAutologous stem cell transplantMedian age 69 yearsAllogeneic stem cell transplantPeripheral T-cell lymphomaTherapy warrants further investigationDisease controlLarge B-cell lymphomaDose level 1Dose level 2Doses of vorinostat
2008
A Retrospective Comparison of Autologous Vs. Allogeneic Transplantation for Peripheral T-Cell Lymphoma: A Single Institution Experience
Lansigan F, Seropian S, Cooper D, Foss F. A Retrospective Comparison of Autologous Vs. Allogeneic Transplantation for Peripheral T-Cell Lymphoma: A Single Institution Experience. Blood 2008, 112: 4392. DOI: 10.1182/blood.v112.11.4392.4392.Peer-Reviewed Original ResearchPeripheral T-cell lymphomaCutaneous T-cell lymphomaAngioimmunoblastic T-cell lymphomaT-cell lymphomaAlloSCT groupNon-Hodgkin lymphomaFirst remissionComplete remissionPartial remissionDonor transplantsAggressive peripheral T-cell lymphomaRefractory cutaneous T-cell lymphomaSurvival rateMatched-unrelated donor transplantProgression-free survival ratesTransplant-related mortality rateAllogeneic stem cell transplantationHepatosplenic T-cell lymphomaPanniculitic T-cell lymphomaAnaplastic large cell lymphomaFirst complete remissionNon-relapse mortalityReduced-intensity transplantsSecond complete remissionOverall survival rate